Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
In patients with HCC who progressed on first-line atezolizumab plus bevacizumab, sorafenib and lenvatinib were the most commonly used second-line regimens in Asia-Pacific countries, with lenvatinib resulting in longer OS than sorafenib. The second-line TKI plus ICI combination exhibited promising efficacy, suggesting the potential role of continuing ICIs beyond disease progression.
Authors
- Choong‐kun Lee (ORCID: https://orcid.org/0000-0001-5151-5096)
- Suebpong Tanasanvimon (ORCID: https://orcid.org/0000-0002-3904-4719)
- Jung Yong Hong (ORCID: https://orcid.org/0000-0003-1363-9332)
- Seok Jae Huh (ORCID: https://orcid.org/0009-0008-8548-5153)
- Krittiya Korphaisarn (ORCID: https://orcid.org/0000-0001-5739-0175)
- Myung Ah Lee (ORCID: https://orcid.org/0000-0002-1204-0574)
- Chia‐Jui Yen (ORCID: https://orcid.org/0000-0001-8744-6248)
- San‐Chi Chen (ORCID: https://orcid.org/0000-0002-9436-5400)
- Landon L. Chan (ORCID: https://orcid.org/0000-0002-1306-5896)
- Stephen L. Chan (ORCID: https://orcid.org/0000-0001-8998-5480)
- Raghav Sundar (ORCID: https://orcid.org/0000-0001-9423-1368)
- Hong Jae Chon (ORCID: https://orcid.org/0000-0002-6979-5812)
- Beodeul Kang (ORCID: https://orcid.org/0000-0001-5177-8937)
- Hye Jin Choi (ORCID: https://orcid.org/0000-0001-5917-1400)
- Dong Ki Lee (ORCID: https://orcid.org/0000-0002-0048-9112)
- Ching-Tso Chen (ORCID: https://orcid.org/0000-0003-0116-9396)
- Moonho Kim (ORCID: https://orcid.org/0000-0002-1777-3267)
- Hong-Sik Kim (ORCID: https://orcid.org/0000-0003-1232-9439)
- Changhoon Yoo (ORCID: https://orcid.org/0000-0002-1451-8455)
- Jin Won Kim (ORCID: https://orcid.org/0000-0002-1357-7015)
- Se Jun Park (ORCID: https://orcid.org/0000-0001-5486-9818)
- Sang-Bo Oh (ORCID: https://orcid.org/0000-0001-7257-0350)
- Il Hwan Kim (ORCID: https://orcid.org/0000-0003-4166-6303)
- Sejung Park (ORCID: https://orcid.org/0000-0003-1728-2465)
- Hyeyeong Kim (ORCID: https://orcid.org/0000-0003-1242-7872)
- David Wai Meng Tai
- Joan Choo
- Woo Kyun Bae
- Ju Kim
- Minsu Kang
Institutions
- Ulsan College (KR)
- Siriraj Hospital (TH)
- Chinese University of Hong Kong (HK)
- Yonsei University (KR)
- Mahidol University (TH)
- Korea University Medical Center (KR)
- Dong-A University Hospital (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- King Chulalongkorn Memorial Hospital (TH)
- Taipei Veterans General Hospital (TW)
- Seoul National University Bundang Hospital (KR)
- University of Ulsan (KR)
- Chonnam National University Hospital (KR)
- Inje University Haeundae Paik Hospital (KR)
- National University Cancer Institute, Singapore (SG)
- Prince of Wales Hospital (CN)
- Pusan National University Hospital (KR)
- National Taiwan University Hospital (TW)
- CHA University Bundang Medical Center (KR)
- Ulsan University Hospital (KR)
- National Cancer Centre Singapore (SG)
- Gangneung Asan Hospital (KR)
- Chonnam National University Hwasun Hospital (KR)
- CHA University (KR)
- Pusan National University Yangsan Hospital (KR)
- National Cheng Kung University Hospital (TW)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Chungbuk National University Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Liver Cancer
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1159/000540969
- Citations
- 12
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 4.43
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Celgene
- Lunit
- Natera
- Eisai
- Astellas Pharma
- Servier
- Ipsen
- Sirtex Medical